Posts tagged: erroneous
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patients With Colorectal Cancer
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biopharmaceuticals (NASDAQ: KERX) was mentioned in a published article which contained an inaccurate statement regarding the design of a pending Phase III study ...